Comparison of Methods in Post Operative Hip Arthroscopy Rehabilitation
Launched by UNIVERSITY OF COLORADO, DENVER · Dec 16, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help people recover after hip surgery, specifically hip arthroscopy, which is a procedure used to treat various hip injuries. The study will test a method called blood flow restriction (BFR) therapy, which has been shown to aid in recovery by using special cuffs to limit blood flow to the muscles during rehabilitation exercises. The researchers are partnering with SAGA, a company that provides smart training technology, to use their BFR cuffs along with standard physical therapy practices for patients in the intervention group.
To be eligible for this trial, participants should be between the ages of 18 and 75 and have specific hip issues like labral tears or impingement syndrome that will be treated with hip arthroscopy. They must also have a smartphone to access the free SAGA BFR application. However, individuals with certain conditions, such as recent blood clots or untreated high blood pressure, cannot participate. Those who join the study can expect to follow a rehabilitation program that incorporates BFR therapy, which could potentially enhance their recovery after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with labral tears, femoroacetabular impingement syndrome, loose bodies, ligamentum teres tears, and related intra-articular pathology to be treated with hip arthroscopy. Patients must also have access to a smartphone device in order to utilize the SAGA BFR application for use. The application is free to use.
- Exclusion Criteria:
- * bilateral hip surgeries to be performed within 12 weeks of each other, concomitant Peri-acetabular osteotomy, soft tissue repairs (hamstring, glute repairs), clinically diagnosed hip dysplasia, and the following BFR contraindications:
- • Deep Vein Thrombosis (DVT)
- • Pulmonary Embolism
- • Hemorrhagic/Thrombolytic Stroke
- • Clotting Disorders
- • Hemophilia or taking blood thinners
- • Pregnant or up to 6 months post-partum
- • Untreated Hypertension
- • Untreated Hypotension
- • Rhabdomyolysis or recent traumatic injury
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Englewood, Colorado, United States
Patients applied
Trial Officials
James Genuario, MD
Principal Investigator
University of Colorado SOM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials